|
Feasibility of multiple immunoexpression assay for immune tumor micrornvironment (I-TME) on matched metastatic and primary renal cell carcinoma (RCC) for patient prognostication and predictiveness to immunotherapy (preliminary analyses of the Meet URO 18 study). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen-Cilag; MSD |
|
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Sanofi |
Other Relationship - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Sanofi/Aventis |
|
|
|
Consulting or Advisory Role - Bristol Myers Squibb; Ipsen; Novartis; Pfizer |
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; Novartis; Pfizer; Pierre Fabre |
Research Funding - Novartis (Inst); Pfizer (Inst); Roche (Inst); Seqirus (Inst) |
Expert Testimony - Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; MSD Oncology; Novartis; Pfizer/EMD Serono; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche |
|
|
Consulting or Advisory Role - Astellas Oncology; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD; Novartis; Pfizer; Sanofi |
Travel, Accommodations, Expenses - Astellas Oncology; Bayer; Janssen |